Introduction: It has been previously shown that adult mesenchymal stem cells (MSCs) differentiate into neural progenitor cells (NPCs) and that the differentiation process was completed in 24–48 h. In this previous study, MSCs from a bone marrow or fat source were co-incubated with homologous autoaggressive cells (ECs) against nerve tissue, and these NPCs were successfully used in human regenerative therapeutic approaches. The present study was conducted to investigate whether a similar differentiation method could be used to obtain autologous retinal progenitor cells (RPCs). Methods: Human Th1 cells against retinal tissue were obtained by challenging human blood mononuclear cells with an eye lysate of bovine origin; negative selection was performed using a specific immunomagnetic bead cocktail. Fat MSCs were obtained from a human donor through mechanical and enzymatic dissociation of a surgical sample. The ECs and MSCs were co-cultured in a serum-free medium without the addition of cytokines for 0, 24, 48 and 72 h. The plastic adherent cells were morphologically examined using inverted-phase microscopy and characterized by immunofluorescent staining using antibodies against Pax 6, TUBB3, GFAP, Bestrophin 2, RPE 65, OPN1 SW, and rhodopsin antigens. Results: The early signs of MSC differentiation into RPCs were observed at 24 h of co-culture, and the early differentiated retinal linage cells appeared at 72 h (neurons, rods, Müller cells, retinal ganglion cells and retinal pigmented epithelial cells). These changes increased during further culture. Conclusion: The results reported here support the development of a method to obtain a large number of autologous adult RPCs, which could be used to treat different retinopathies.

Journal Section:
Paper
Keywords:
Stem cells, Retinal progenitor cells, Adult mesenchymal stem cells
1.
Jeganathan VS, Palanisamy M: Treatment viability of stem cells in ophthalmology. Curr Opin Ophthalmol 2010;21:213–217.
https://doi.org/10.1097%2FICU.0b013e32833867ad
2.
European Medicines Agency (EMEA). Committee for Advanced Therapies (CAT) Reflection paper on stem cell-based medicinal products. 14 January 2011 EMA/CAT/ 571134/2009.
3.
Singh MS, MacLaren RE: Stem cells as a therapeutic tool for the blind: biology and future prospects. Proc Biol Sci 2011;278:3009–3016.
https://doi.org/10.1098%2Frspb.2011.1028
4.
Takahashi M, Palmer TD, Takahashi J, Gage FH: Widespread integration and survival of adult-derived neural progenitor cells in the developing optic retina. Mol Cell Neurosci 1998;12:340–348.
[PubMed]
https://doi.org/10.1006%2Fmcne.1998.0721
5.
Young MJ, Ray J, Whiteley SJ, Klassen H, Gage FH: Neuronal differentiation and morphological integration of hippocampal progenitor cells transplanted to the retina of immature and mature dystrophic rats. Mol Cell Neurosci 2000;16:197–205.
[PubMed]
https://doi.org/10.1006%2Fmcne.2000.0869
6.
Moviglia GA, Varela G, Gaeta CA, Brizuela JA, Bastos F, Saslavsky J: Autoreactive T cells induce in vitro bone marrow mesenchymal stem cells transdifferentiation to neural stem cells. Cytotherapy 2006;8:196–201.
https://doi.org/10.1080%2F14653240600735958
7.
Moviglia GA, Fernandez Viña R, Brizuela JA, Saslavsky J, Vrsalovic F, Varela G, Bastos F, Farina P, Etchegaray G, Barbieri M, Martinez G, Picasso F, Schmidt Y, Brizuela P, Gaeta CA, Costanzo H, Moviglia Brandolino MT, Merino S, Pes ME, Veloso MJ, Rugilo C, Tamer I, Shuster GS: Combined protocol of cell therapy for chronic spinal cord injury: report on the electrical and functional recovery of two patients. Cytotherapy 2006;8:202–209.
https://doi.org/10.1080%2F14653240600736048
8.
Moviglia GA, Varela G, Brizuela JA, Moviglia Brandolino MT, Farina P, Etchegaray G, Piccone S, Hirsch J, Martinez G, Marino S, Deffain S, Coria N, Gonzáles A, Sztanko M, Salas-Zamora P, Previgliano I, Aingel V, Farias J, Gaeta CA, Saslavsky J, Blasseti N: Case report on the clinical results of a combined cellular therapy for chronic spinal cord injured patients. Spinal Cord 2009;47:499–503.
https://doi.org/10.1038%2Fsc.2008.164
9.
Mosna F, Sensebé L, Krampera M: Human bone marrow and adipose tissue mesenchymal stem cells: a user’s guide. Stem Cells Dev 2010;19:1449–1470.
https://doi.org/10.1089%2Fscd.2010.0140
10.
Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, Bunnell BA: Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 2008;68:4229–4238.
[PubMed]
https://doi.org/10.1158%2F0008-5472.CAN-07-5272
11.
Buchholz DE, Hikita ST, Rowland TJ, Friedrich AM, Hinman CR, Johnson LV, Clegg DO: Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells 2009;27: 2427–2434.
https://doi.org/10.1002%2Fstem.189
12.
Liao JL, Yu J, Huang K, Hu J, Diemer T, Ma Z, Dvash T, Yang XJ, Travis GH, Williams DS, Bok D, Fan G: Molecular signature of primary retinal pigment epithelium and stem-cell-derived RPE cells. Hum Mol Genet 2010;19:4229–4238.
https://doi.org/10.1093%2Fhmg%2Fddq341
13.
Hollborn M, Ulbricht E, Rillich K, Dukic-Stefanovic S, Wurm A, Wagner L, Reichenbach A, Wiedemann P, Limb GA, Bringmann A, Kohen L: The human Müller cell line MIO-M1 expresses opsins. Mol Vis 2011;17:2738–2750.
14.
Wohl SG, Schmeer CW, Friese T, Witte OW, Isenmann S: In situ dividing and phagocytosing retinal microglia express nestin, vimentin, and NG2 in vivo. PLoS One 2011;6:e22408.
https://doi.org/10.1371%2Fjournal.pone.0022408
15.
Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M: Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999;5:49–55.
[PubMed]
https://doi.org/10.1038%2F4734
16.
Barouch R, Schwartz M: Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: implications for protective autoimmunity. FASEB J 2002;16:1304–1306.
[PubMed]
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.